NCT01995981View on ClinicalTrials.gov

Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS

CompletedOBSERVATIONAL
Enrollment

22

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

November 10, 2017

Study Completion Date

November 10, 2017

Conditions
Sarcoma, Soft Tissue
Interventions
DRUG

Pazopanib

Trial Locations (2)

6525 GA

Radboud University Nijmegen Medical Centre, Nijmegen

Unknown

Royal Marsden Hospital, London

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT01995981 - Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS | Biotech Hunter | Biotech Hunter